Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04640571 · ClinicalTrials.gov registry record · Phase 4
Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition
A Phase 4 study of Bile Salt Export Pump (BSEP) Transporter and Polysorbate 80, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT04640571 is a Phase 4 study of Bile Salt Export Pump (BSEP) Transporter and Polysorbate 80 that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04640571, a Phase 4 study of Bile Salt Export Pump (BSEP) Transporter and Polysorbate 80, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The study employs two-sub-studies that share a common placebo arm. The objective of one sub-study is to assess the impact of metformin on pravastatin and chenodeoxycholic acid pharmacokinetics. We hypothesize that metformin represses the bile salt export pump (BSEP) in the liver, which excretes pravastatin and chenodeoxycholic acid from the liver into the bile. The objective of the other sub-study is to assess the impact of polysorbate 80 on valacyclovir, chenodeoxycholic acid, and enalaprilat pharmacokinetics. We hypothesize that polysorbate 80 inhibits uptake transporters in the intestine, which absorb valacyclovir and chenodeoxycholic acid in the gut via the peptide transporter 1 (PepT1) and apical sodium-bile acid transporter (ASBT), respectively. Enalaprilat is passively absorbed but with low permeability, and thus serves as a passive absorption reference.
Conditions Studied
Interventions
- DRUG pravastatin and chenodeoxycholic acid, after metformin and placebo
- DRUG valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo
Study Locations (1)
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2021-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04640571
The ClinicalTrials.gov registry entry for NCT04640571 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bile Salt Export Pump (BSEP) Transporter appearing as the primary indexed condition, and to 2 interventions - of which pravastatin and chenodeoxycholic acid, after metformin and placebo is the first listed.
NCT04640571 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04640571 about?
NCT04640571 is a clinical study titled "Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition". The study employs two-sub-studies that share a common placebo arm. The objective of one sub-study is to assess the impact of metformin on pravastatin and chenodeoxycholic acid pharmacokinetics. We hypothesize that metformin represses the bile salt export pump (BSEP) in the liver, which excretes pra...
What is the current status of trial NCT04640571?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2021-04-01. Estimated completion is 2021-11-01.
What conditions does trial NCT04640571 study?
This clinical trial studies the following conditions: Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80.
What interventions are being tested in trial NCT04640571?
The interventions under investigation include: pravastatin and chenodeoxycholic acid, after metformin and placebo (DRUG), valacyclovir, chenodeoxycholic acid, and enalaprilat, after polysorbate 80 and placebo (DRUG).
Who is sponsoring clinical trial NCT04640571?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04640571 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.